REG - Eden Research plc - Posting of Annual Report & Notice of AGM <Origin Href="QuoteRef">EDENE.L</Origin>

Eden ResearchAnnouncement

05/06/2017 15:15

RNS Number : 1827H
Eden Research plc
05 June 2017
Eden Research Plc
("Eden" or "Company")
Posting of Annual Report & Notice of AGM
Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its Annual Report and Accounts for the year ended 31 December 2016, Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders and are now available on the Company's website: www.edenresearch.com
The AGM is to be held on Friday 30 June 2017 at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED. 
Eden Research plc  
www.edenresearch.com
Sean Smith, Chief Executive Officer
Tel: 01285 359 555
Alex Abrey, Chief Financial Officer



Shore Capital and Corporate Limited 
www.shorecap.com
Stephane Auton/Patrick Castle
Tel: 020 7408 4090


Walbrook PR Ltd
Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
Notes:
EdenResearch is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of 12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.
In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.To illustrate this point, one should notethat in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.
3AEY has been authorised for sale in Kenya, Malta, Greece, Bulgaria, Spain, Italy, France, Cyprus and Albania.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit:www.edenresearch.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCMMGGVDKZGNZM